Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Meaney, A. M.
Right arrow Articles by O’Keane, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meaney, A. M.
Right arrow Articles by O’Keane, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Reduced Bone Mineral Density in Patients with Schizophrenia Receiving Prolactin Raising Anti-Psychotic Medication

Anna Maria Meaney

Waterford Regional Hospital, Waterford, Ireland, London, UKannamariameaney{at}hotmail.com

Veronica O’Keane

Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, UK

Patients with schizophrenia frequently develop drug-induced hyperprolactinaemia and consequent hypogonadism. Reduced bone mineral density as a consequence of hyperprolactinaemia-induced hypogonadism has been well documented in medical, but not psychiatric, disorders. Little attention has been given to the potential risk of developing osteoporosis secondary to anti-psychotic-induced hyperprolactinaemia. Three cases are presented that illustrate how this debilitating but silent disease may affect even those young individuals with schizophrenia.

Key Words: osteoporosis • prolactin • schizophrenia

Journal of Psychopharmacology, Vol. 17, No. 4, 455-458 (2003)
DOI: 10.1177/0269881103174011
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
D. Kohen and H. J. Wildgust
The evolution of hyperprolactinaemia as an entity in psychiatric patients
J Psychopharmacol, March 1, 2008; 22(2_suppl): 6 - 11.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
C. Bushe, M. Shaw, and R. C Peveler
A review of the association between antipsychotic use and hyperprolactinaemia
J Psychopharmacol, March 1, 2008; 22(2_suppl): 46 - 55.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
C. Bushe, D. Yeomans, T. Floyd, and S. M Smith
Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics
J Psychopharmacol, March 1, 2008; 22(2_suppl): 56 - 62.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
C. Bushe and M. Shaw
Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics
J Psychopharmacol, September 1, 2007; 21(7): 768 - 773.
[Abstract] [PDF]


Advertisement